Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

C0430000

Captopril

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
138,00 €

138,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
10 MG
138,00 €

About This Item

Formula empirica (notazione di Hill):
C9H15NO3S
Numero CAS:
62571-86-2
Peso molecolare:
217.29
Beilstein:
477887
Numero MDL:
MFCD00168073
Codice UNSPSC:
41116107
ID PubChem:
329774790
NACRES:
NA.24

138,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Grado

pharmaceutical primary standard

Famiglia di API

captopril

Produttore/marchio commerciale

EDQM

Punto di fusione

104-108 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
FAKRSMQSSFJEIM-RQJHMYQMSA-N

Informazioni sul gene

human ... ACE(1636)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Captopril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

1091200

Captopril, United States Pharmacopeia (USP) Reference Standard

1091221

Captopril disulfide, United States Pharmacopeia (USP) Reference Standard

Y0000435

Captopril impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001182

Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril impurity D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril impurity J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captopril disulfide, British Pharmacopoeia (BP) Reference Standard

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H341,H360F

Consigli di prudenza

P201 - P308 + P313

Classi di pericolo

Muta. 2 - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

Sodium nitrate ReagentPlus®, ≥99.0%

Sigma-Aldrich

S5506

Sodium nitrate

Potassio ftalato monobasico BioXtra, ≥99.95%

Sigma-Aldrich

P1088

Potassio ftalato monobasico

Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
Javed Mahmood et al.
International journal of radiation oncology, biology, physics, 89(4), 722-728 (2014-05-29)
To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats. The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose
Kyung Hee Chang et al.
Nature communications, 6, 5914-5914 (2015-01-13)
Patients with organ failure of vascular origin have increased circulating haematopoietic stem cells and progenitors (HSC/P). Plasma levels of angiotensin II (Ang-II), are commonly increased in vasculopathies. Hyperangiotensinemia results in activation of a very distinct Ang-II receptor set, Rho family
Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.